Clinical trials: HER2
Cancer, Metastases
BMS-599626 in Patients With Advanced Solid Malignancies
The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21 days with a 7 day rest period in patients…
- Trial name
- NCT00095537
- Testing
- panHer
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Breast Cancer
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
The purpose of this research study is to look at the effectiveness of a combination of doxil, carboplatin and bevacizumab on metastatic breast cancer.
- Trial name
- NCT00608972
- Testing
- Doxil, Carboplatin, Bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rutgers, The State University of New Jersey
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence.
- Trial name
- NCT04622319
- Testing
- DS-8201a, T-DM1
- Where
- 482 sites in United States, Argentina and 29 more
- Volunteers
- 1,600 people
- Sponsor
- Daiichi Sankyo
Recurrent or Metastatic Breast Cancer
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.
- Trial name
- OPTIMAL (NCT03315364)
- Testing
- Oral paclitaxel, Paclitaxel injection
- Where
- 51 sites in Bulgaria, China and 3 more
- Volunteers
- 549 people
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
Breast Cancer
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
The researchers want to learn whether ZD1839 can improve the activity of tamoxifen, a drug that participants will receive for the treatment of the type of breast cancer being studied.
- Trial name
- NCT00206492
- Testing
- Iressa, Tamoxifen
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Baylor Breast Care Center
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
- Conditions
- Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer
- Trial name
- PACT (NCT02791334)
- Testing
- LY3300054, Ramucirumab, Abemaciclib
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer
A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
The investigators hypothesis is that the combination of TS-ONE with cisplatin and trastuzumab is safe and as effective as combination treatment for HER2 positive gastric cancer.
- Trial name
- NCT01228045
- Testing
- Trastuzumab in Combination with TS-ONE and cisplatin
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Tka Assay for CDK4/6i
This clinical trial assesses whether using a test developed by DiviTum can identify optimal levels of CDK 4/6 inhibitor medications in the blood and whether assessing medical compliance and drug-drug interactions can optimize…
- Trial name
- NCT06572800
- Testing
- DiviTum-TKa
- Where
- 18 sites in United States
- Volunteers
- 34 people
- Sponsor
- Yale University
Chordoma, HER2-positive Breast Cancer
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
A Phase 1 open label trial of intravenous administration of TAEK-VAC-HerBy vaccine in patients with advanced brachyury and/or HER2- expressing cancer. The study will be completed in 2 stages.
- Trial name
- NCT04246671
- Testing
- TAEK-VAC-HerBy
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- Bavarian Nordic
Advanced Breast Cancer, Objective Response Rate
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
The goal of this clinical trial is to learn about the efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of patients with advanced HER2-positive breast cancer after TKIs or HP therapy.
- Conditions
- Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine
- Trial name
- NCT06125834
- Testing
- Trastuzumab Emtansine (T-DM1)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Adenocarcinoma
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e.
- Trial name
- FIDES-03 (NCT04604132)
- Testing
- Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
- Where
- 81 sites in United States, Argentina and 13 more
- Volunteers
- 47 people
- Sponsor
- Basilea Pharmaceutica
Breast Cancer
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery.
- Trial name
- NCT02520063
- Testing
- Letrozole, Everolimus, TRC105
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Breast Cancer
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
- Trial name
- Dauntless-1 (NCT04115306)
- Testing
- PMD-026, fulvestrant
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Phoenix Molecular Designs
EGFR Exon 20 Mutation, ERBB2 Gene Mutation
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent).
- Conditions
- EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03066206
- Testing
- Poziotinib
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
- Trial name
- NCT03843749
- Testing
- Pyrotinib
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Breast Cancer
GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting
Non-interventional, multicenter, prospective observational study of tucatinib-trastuzumab capecitabine administered according to the standard local clinical practice following approved SmPC indication and dose.
- Trial name
- THERapy (NCT07583485)
- Where
- 30 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Oncotech
Breast Neoplasms
Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
PF-04691502 is an inhibitor of PI3K and mTOR kinase. Exemestane is an aromatase inhibitor for the treatment of advanced breast cancer in women whose disease has progressed following tamoxifen therapy.
- Trial name
- NCT01658176
- Testing
- PF-04691502, Exemestane
- Sponsor
- Pfizer
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations.
- Trial name
- SOLARA (NCT06706076)
- Testing
- BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 675 people
- Sponsor
- BlossomHill Therapeutics
Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer…
- Conditions
- Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT01700582
- Where
- 133 sites in France
- Volunteers
- 17,664 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Breast Cancer
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
Patients with estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) breast cancer do not achieve good responses with pre-operative chemotherapy.
- Trial name
- NCT05069038
- Testing
- Palbociclib 125mg
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Nebraska